Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6D
|
pubmed:dateCreated |
1998-3-26
|
pubmed:abstractText |
Vinblastine (VELBE) is one of the first chemotherapeutic agents used in the treatment of malignancies. To explore the effectiveness of various treatment regimens, bolus versus 24-hour continuous VELBE treatment was tested on an EAT tumor model in mice. Continuous VELBE infusion was simulated by splitting the bolus VELBE dose into 4 fractions, injected at 8-hour intervals. A comparison of antitumor effectiveness between bolus and split dose VELBE treatment was determined by three assays: cell survival, tumor growth delay and animal survival. The cell survival curves of both bolus and split dose VELBE treatments indicated a biphasic response with an initial fast reduction in cell survival followed by a plateau. However, split dose treatment was significantly more effective than bolus treatment at all doses tested (p < 0.001). Tumor growth delay of the split dose VELBE treatment was 6.9 days and of the bolus VELBE treatment 3.0 days, indicating that the split dose treatment is approximately 2-times more effective (p < 0.001). Median survival time of mice treated with split VELBE dose (24.0 days) was significantly longer compared to that of mice treated with bolus VELBE dose (16.5 days) (p < 0.001). The median survival time of control untreated mice (16.0 days) and bolus treated mice did not differ (p = 0.24). Our study shows that at the same VELBE dose the split dose VELBE treatment is more effective than VELBE administered in bolus.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0250-7005
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
4553-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9494567-Animals,
pubmed-meshheading:9494567-Carcinoma, Ehrlich Tumor,
pubmed-meshheading:9494567-Cell Division,
pubmed-meshheading:9494567-Cell Survival,
pubmed-meshheading:9494567-Drug Administration Schedule,
pubmed-meshheading:9494567-Female,
pubmed-meshheading:9494567-Injections, Intraperitoneal,
pubmed-meshheading:9494567-Male,
pubmed-meshheading:9494567-Mice,
pubmed-meshheading:9494567-Mice, Inbred CBA,
pubmed-meshheading:9494567-Vinblastine
|
pubmed:articleTitle |
Antitumor effectiveness of bolus versus split dose vinblastine treatment in EAT tumors in mice.
|
pubmed:affiliation |
Institute of Oncology, Ljubljana, Slovenia.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|